The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke

We evaluated the effects of beraprost Na (Sodium (+-)-(1R*,2R*, 3aS*,8bS*)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(E)-(3S*)-3- hyd roxy-4-methyl-1- octen-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butylate, beraprost), a stable and orally active prostacyclin (PGI2) analog with potent antiplatelet and vasodilat...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and chemical neuropathology 1992-08, Vol.17 (1), p.91-102
Main Authors: HIRANO, T, YAMORI, Y, KANAI, N, UMETSU, T, NISHIO, S
Format: Article
Language:English
Subjects:
Animals
Antianginal agents. Coronary vasodilator agents
Arachidonic Acid
Biological and medical sciences
Blood Pressure - drug effects
Body Weight - drug effects
Cardiovascular system
Cerebrovascular Circulation - drug effects
Cerebrovascular Disorders - chemically induced
Cerebrovascular Disorders - drug therapy
Cerebrovascular Disorders - mortality
Death, Sudden
Diltiazem - therapeutic use
Epoprostenol - analogs & derivatives
Epoprostenol - pharmacology
Male
Medical sciences
Pharmacology. Drug treatments
Platelet Aggregation Inhibitors - pharmacology
Rabbits
Rats
Rats, Inbred SHR
Ticlopidine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the effects of beraprost Na (Sodium (+-)-(1R*,2R*, 3aS*,8bS*)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(E)-(3S*)-3- hyd roxy-4-methyl-1- octen-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butylate, beraprost), a stable and orally active prostacyclin (PGI2) analog with potent antiplatelet and vasodilating properties, on two stroke models, namely sudden death induced by arachidonate (AA) in rabbits and spontaneous stroke in stroke-prone spontaneously hypertensive rats (SHRSP). In the AA-induced sudden death model, 30 min after beraprost administration (1 or 3 mg/kg, po), AA was injected into the rabbit internal carotid artery, and incidence of convulsion and sudden death were assessed. Beraprost decreased both incidence of convulsion and mortality of rabbits. In SHRSP, orally administered beraprost (100 micrograms/kg, twice a day from 56-385 d of age) improved survival rate and decreased incidence of stroke. Preventive effects of beraprost on the two stroke models may have been caused mainly by the improvement of cerebral circulation. These results indicate that beraprost may have potential in the treatment and/or prevention of the cerebral circulatory disorders.
ISSN:1044-7393
2168-8729
DOI:10.1007/bf03159984